Loading...

We've got a brand new version of Simply Wall St! Try it out

International Cannabrands

CNSX:JUJU
Snowflake Description

Imperfect balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
JUJU
CNSX
CA$9M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

International Cannabrands Inc. licenses brands to growers, edible manufacturers, oil extractors, and producers of ancillary products and apparel in the United States and internationally. The last earnings update was 22 days ago. More info.


Add to Portfolio Compare Print
  • International Cannabrands has significant price volatility in the past 3 months.
JUJU Share Price and Events
7 Day Returns
-14.3%
CNSX:JUJU
-0.2%
CA Pharmaceuticals
1.2%
CA Market
1 Year Returns
-90.2%
CNSX:JUJU
-45.8%
CA Pharmaceuticals
-0.4%
CA Market
JUJU Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
International Cannabrands (JUJU) -14.3% -33.3% -53.8% -90.2% - -
CA Pharmaceuticals -0.2% -1.8% -21.5% -45.8% 251% 334.4%
CA Market 1.2% 3.3% 0.8% -0.4% 7.4% 4.5%
1 Year Return vs Industry and Market
  • JUJU underperformed the Pharmaceuticals industry which returned -45.8% over the past year.
  • JUJU underperformed the Market in Canada which returned -0.4% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

JUJU Value

 Is International Cannabrands undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for International Cannabrands. This is due to cash flow or dividend data being unavailable. The share price is CA$0.03.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for International Cannabrands's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are International Cannabrands's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:JUJU PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in USD $-0.04
CNSX:JUJU Share Price ** CNSX (2019-09-19) in CAD CA$0.03
CNSX:JUJU Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $0.02
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 18.72x
Canada Market PE Ratio Median Figure of 540 Publicly-Listed Companies 14.11x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of International Cannabrands.

CNSX:JUJU PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:JUJU Share Price ÷ EPS (both in USD)

= 0.02 ÷ -0.04

-0.54x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • International Cannabrands is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • International Cannabrands is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does International Cannabrands's expected growth come at a high price?
Raw Data
CNSX:JUJU PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.54x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.57x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for International Cannabrands, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on International Cannabrands's assets?
Raw Data
CNSX:JUJU PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in USD $0.01
CNSX:JUJU Share Price * CNSX (2019-09-19) in CAD CA$0.03
CNSX:JUJU Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $0.02
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.32x
Canada Market PB Ratio Median Figure of 2,454 Publicly-Listed Companies 1.44x
CNSX:JUJU PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:JUJU Share Price ÷ Book Value per Share (both in USD)

= 0.02 ÷ 0.01

3.06x

* Primary Listing of International Cannabrands.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • International Cannabrands is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess International Cannabrands's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. International Cannabrands has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

JUJU Future Performance

 How is International Cannabrands expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as International Cannabrands has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
110.6%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is International Cannabrands expected to grow at an attractive rate?
  • Unable to compare International Cannabrands's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare International Cannabrands's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare International Cannabrands's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:JUJU Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 110.6%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 58.6%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.8%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:JUJU Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:JUJU Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-06-30 3 -3 -9
2019-03-31 1 -5 -8
2018-12-31 0 -2 -4
2018-09-30 0 -2 -3
2018-06-30 0 -2 -2
2018-03-31 0 -2 -1
2017-12-31 0 -1 -1
2017-09-30 0 -1 -1
2017-03-31 0 0 -1
2016-12-31 0 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if International Cannabrands is high growth as no earnings estimate data is available.
  • Unable to determine if International Cannabrands is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:JUJU Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from International Cannabrands Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:JUJU Past Financials Data
Date (Data in USD Millions) EPS *
2019-06-30 -0.04
2019-03-31 -0.04
2018-12-31 -0.03
2018-09-30 -0.04
2018-06-30 -0.03
2018-03-31 -0.04
2017-12-31 -0.06
2017-09-30 -0.14
2017-03-31 -0.07
2016-12-31 -0.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if International Cannabrands will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. International Cannabrands's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. International Cannabrands's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess International Cannabrands's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
International Cannabrands has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

JUJU Past Performance

  How has International Cannabrands performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare International Cannabrands's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • International Cannabrands does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare International Cannabrands's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare International Cannabrands's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
International Cannabrands's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from International Cannabrands Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:JUJU Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 3.06 -9.31 3.05
2019-03-31 1.28 -7.65 2.69
2018-12-31 0.11 -4.44 1.85
2018-09-30 0.15 -3.22 1.65
2018-06-30 0.17 -1.89 1.27
2018-03-31 0.16 -1.47 1.21
2017-12-31 0.14 -1.40 1.30
2017-09-30 0.16 -1.30 1.03
2017-03-31 0.39 -0.71 0.67
2016-12-31 0.39 -0.39 0.37
2015-12-31 0.02 -0.58 0.53

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if International Cannabrands has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if International Cannabrands has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if International Cannabrands improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess International Cannabrands's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
International Cannabrands has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

JUJU Health

 How is International Cannabrands's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up International Cannabrands's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • International Cannabrands's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • International Cannabrands's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of International Cannabrands's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from International Cannabrands Company Filings, last reported 2 months ago.

CNSX:JUJU Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 7.39 2.04 0.85
2019-03-31 8.95 2.62 1.50
2018-12-31 2.07 0.93 0.67
2018-09-30 0.93 0.92 1.35
2018-06-30 -0.75 0.94 0.03
2018-03-31 -0.36 0.94 0.31
2017-12-31 -0.69 0.93 0.11
2017-09-30 -0.58 0.93 0.33
2017-03-31 -0.84 0.91 0.00
2016-12-31 -0.80 0.94 0.01
2015-12-31 -0.41 0.63 0.03
  • International Cannabrands's level of debt (27.6%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if International Cannabrands's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • International Cannabrands has less than a year of cash runway based on current free cash flow.
  • International Cannabrands has less than a year of cash runway if free cash flow continues to grow at historical rates of 86.8% each year.
X
Financial health checks
We assess International Cannabrands's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. International Cannabrands has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

JUJU Dividends

 What is International Cannabrands's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from International Cannabrands dividends.
If you bought CA$2,000 of International Cannabrands shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate International Cannabrands's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate International Cannabrands's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:JUJU Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as International Cannabrands has not reported any payouts.
  • Unable to verify if International Cannabrands's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of International Cannabrands's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as International Cannabrands has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess International Cannabrands's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can International Cannabrands afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. International Cannabrands has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

JUJU Management

 What is the CEO of International Cannabrands's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steve Gormley
AGE 52
TENURE AS CEO 1.2 years
CEO Bio

Mr. Steven Gormley, also known as Steve, has been President and Chief Executive Officer of International Cannabrands Inc. since July 2018 and as its Director since April 16, 2018. He serves as a Founder, Managing Partner, and Chief Executive Officer at Seventh Point LLC. He serves as COO of Silverback Investments, Inc. He also serves as President of Alta Via Ventures, LLC, a management services company to licensed cannabis businesses in the Los Angeles, California operator. He has operated a hydroponics retail gardening supply enterprise in Los Angeles as well as licensed cultivation facilities in California. He served as Acting Secretary of OSL Holdings Inc. since April 11, 2014. Mr. Gormley served as the Chief Corporate Development Officer of OSL Holdings Inc. He served as the Chief Business Development Officer of OSL Holdings Inc. from April 11, 2014 to March 2016. Mr. Gormley served as the President of Equality Rewards Division at OSL Holdings Inc. since January 2013. Mr. Gormley served as a consultant from July 2012 until January 2013. Mr. Gormley served as a Partner in GB Strategic LLC since August 2011. Prior to that, in 2008, he founded Zamaneth Media Consulting where he served as its Chief Executive Officer until October 2011. Prior to that from 2005 to 2008 Mr. Gormley served as Managing Director at Medical Capital Holdings. From 2004 to 2005 Mr. Gormley served as Managing Director at Seed. He also served as Managing Director at American Entertainment Partners from 2000 to 2004 where he was responsible developing, branding, marketing, launching, managing and operations for these companies. Mr. Gormley served as a Director at OSL Holdings Inc. since June 20, 2013. Mr. Gormley received a Bachelor’s of Arts Degree in Political Science from Gettysburg College in 1989 and continued studies in the Chinese language and literature and the privatization of the former Soviet Union. He is a renowned expert in the legal marijuana sector and whose analysis is featured prominently in outlets like Forbes, Wall Street Journal, CBS News, US News and World Report, Chicago Tribune, and Marketwatch. He has over seven years’ experience in the cannabis industry. He has lived and worked in Asia, Europe, South America and Australia. He got his start in media in television production in the early 90s. After developing content and producing for MTV, Paramount Pictures, Tribune and others, he levered his expertise in content into the on-line sector for a new media private equity fund in the late 90’s and early part of the new century. He helped develop, launch, manage and sell a number of new media properties and eventually founded a branded entertainment company in China. He has also served as managing director for a California based media private equity fund. He deployed C-Level Management Services specializing in startups and turn-arounds.

CEO Compensation
  • Insufficient data for Steve to compare compensation growth.
  • Insufficient data for Steve to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the International Cannabrands management team in years:

0.5
Average Tenure
52
Average Age
  • The average tenure for the International Cannabrands management team is less than 2 years, this suggests a new team.
Management Team

Steve Gormley

TITLE
President
AGE
52
TENURE
1.2 yrs

Mark Scott

TITLE
Chief Financial Officer
AGE
66

Alison Bryce

TITLE
Chief Operating Officer
TENURE
0.3 yrs

Jesse Meighan

TITLE
Chief Marketing Officer
TENURE
0.6 yrs

Bethany Stiles

TITLE
Vice President of Sales
TENURE
0.2 yrs

Scott Reeves

TITLE
Secretary & Director
AGE
49
Board of Directors Tenure

Average tenure and age of the International Cannabrands board of directors in years:

0.7
Average Tenure
51
Average Age
  • The average tenure for the International Cannabrands board of directors is less than 3 years, this suggests a new board.
Board of Directors

Neal Pomroy

TITLE
Chairman
TENURE
0.7 yrs

Steve Gormley

TITLE
President
AGE
52
TENURE
1.4 yrs

Scott Reeves

TITLE
Secretary & Director
AGE
49

Travis Belcher

TITLE
Director
AGE
51

Tony Ruggieri

TITLE
Independent Director
TENURE
0.7 yrs

Bryce Berryessa

TITLE
Director
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
11. Oct 18 Buy Robert Pomroy Individual 26. Sep 18 26. Sep 18 619,047 CA$0.21 CA$130,000
X
Management checks
We assess International Cannabrands's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. International Cannabrands has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

JUJU News

Simply Wall St News

JUJU Company Info

Description

International Cannabrands Inc. licenses brands to growers, edible manufacturers, oil extractors, and producers of ancillary products and apparel in the United States and internationally. The company markets the JuJu Royal brand, including JuJu Royal Ultra Premium Cannabis brand to producers and processors to develop branded strains of cannabis, and infused and edible cannabis consumables, as well as ancillary products, including clothing, paraphernalia, posters, and other products. It also provides products containing cannabidiol. The company was formerly known as GEA Technologies Ltd. and changed its name to International Cannabrands Inc. in November 2017. International Cannabrands Inc. was incorporated in 2011 and is headquartered in Denver, Colorado.

Details
Name: International Cannabrands Inc.
JUJU
Exchange: CNSX
Founded: 2011
CA$8,702,605
290,086,862
Website: http://intlcannabrands.com
Address: International Cannabrands Inc.
1045 North Lincoln Street,
Suite 106,
Denver,
Colorado, 80203,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX JUJU Common Shares Canadian National Stock Exchange CA CAD 27. Sep 2017
OTCPK GEAT.F Common Shares Pink Sheets LLC US USD 27. Sep 2017
DB 31G Common Shares Deutsche Boerse AG DE EUR 27. Sep 2017
Number of employees
Current staff
Staff numbers
0
International Cannabrands employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/20 01:27
End of day share price update: 2019/09/19 00:00
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.